BioSpace News Archive

AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been validated by Biocept, Inc., a leading provider of molecular diagnostic assays, products and services.

Astrocyte Pharmaceuticals Inc., today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke.

Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the Piper Sandler 33rd Annual Healthcare Conference, being held virtually.

DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26th Annual Meeting and Education Day of the Society for Neuro-oncology (SNO).

DePuy Synthes, The Orthopaedics Company of Johnson & Johnson*, has launched the UNIUM™ System as the newest addition to its Power Tools portfolio.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) under which GSK will develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis (NASH).

23andMe Holding Co. announced that it will redeem all of its outstanding warrants to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020, by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent, as part of the units sold in the initial public offering of 23andMe, which was formerly known as VG Acquisition Corp., and that remain outstanding at 5:00 p.m.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2021.